UT M.D. Anderson Cancer Center

UT MD 安德森癌症中心

• 批准号: 7281910
• 负责人: MICHAEL Jordan FISCH
• 金额: $ 136.22万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7281910
• 关键词: Address; Adult; Affect; Affective Symptoms; American; Area; Arts; Back; Belief; Cancer Center; Cancer Control; Cancer Control Research Program; Cancer Patient; Cancer Survivor; Caring; Cause of Death; Cessation of life; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials[{..}] Cancer Control; Commit; Communication; Communities; Community Clinical Oncology Program; Complementary and alternative medicine; Conduct Clinical Trials; Controlled Clinical Trials; Development; Diagnosis; Disease; Doctor of Medicine; Faculty; Family; Fatigue; Health; Impaired cognition; Individual; Integrative Medicine; Intervention; Leadership; Life; Malignant Neoplasms; Measurement; Medical; Medicine; Medicine in Art; Mission; Modeling; Neuropathy; Numbers; Oncologist; Outcome Measure; Pain; Palliative Care; Patient Care; Patient Outcomes Assessments; Patients; Population; Prevention; Prevention Research; Rehabilitation therapy; Research; Research Infrastructure; Resources; Risk; Site; Sleep disturbances; Standards of Weights and Measures; Structure; Symptoms; Teaching Hospitals; Technology; Texas; Therapeutic; Touch sensation; United States; Universities; University of Texas M D Anderson Cancer Center; Woman; aging population; base; cancer care; cancer prevention; cancer therapy; design; improved; innovation; interest; knowledge base; lifetime risk; member; men; novel; oncology; patient oriented; prevent; programs; psychologic; psychosocial; response; skills; symptom management; treatment trial

DESCRIPTION (provided by applicant): Approximately 10 million Americans are cancer survivors living in their communities, and 80% of adult cancer care is delivered in the community oncology setting. To implement clinical trials, make progress at an appropriate pace in cancer medicine, and address the vital needs of an aging population, the clinical research infrastructure must extend into the community oncology setting. Our hypothesis is that enriched clinical trials in cancer control care, especially in the areas of symptom prevention, symptom management, integrative medicine, cancer prevention, cancer control, and cancer treatment can be delivered to patients via state-of-the art medicine in their communities through our Research" Base; and subsequently, important cancer care-related information and approaches can be transferred back from the community to M. D. Anderson Cancer Center to enhance our research programs and our understanding of cancer care. Our plan is to complete our existing cancer treatment trials, and to develop no further treatment trials. We will develop an expanded, focused program of cancer control research in response to the current needs of our community oncologists and the field of cancer medicine, the increased number of cancer survivors and the associated challenges in developing research-driven models of care for this population, and the evolving strengths of the M. D. Anderson research faculty. The specific aims of this proposal are: Aim 1.To conduct interventional clinical trials in the realm of cancer control to enhance the health of patients affected by cancer; Sub-aim 1a: To develop and conduct interventional clinical trials in the realm of palliative care and rehabilitation; Sub-aim 1b: To develop and conduct interventional clinical trials in the realm of supportive oncology; Sub-aim 1c: To develop and conduct interventional trials that utilize interventions in the realm of integrative medicine (sometimes called complementary and alternative medicine); Sub-aim 1d: To develop and conduct interventional trials directed at improving the health of cancer survivors; Sub-aim 1e: To draw upon best practices in symptom assessment and measurement, and to expand the knowledge base in these realms through the conduct of interventional clinical trials that include patient-reported outcome measures; Sub-aim 1f: To incorporate novel Bayesian approaches to the design and analysis of clinical trials that include use of patient- reported outcomes. Aim 2. To exchange medical information, scientific technology, and. best practice standards among our academic cancer center faculty and fellows, other academic centers, and community oncology sites through collaborative development of practical, innovative cancer control trials. Our Research Base is committed to directing our research program toward conducting clinical trials to meet our CCOP members' interests, skills, and practice settings while fulfilling the mission of M. D. Anderson and the NCI to eliminate suffering attributable to cancer and its treatments.

描述（由申请人提供）：大约1000万美国人是居住在其社区中的癌症幸存者，在社区肿瘤学的环境中，有80％的成人癌症护理提供。为了实施临床试验，在癌症医学方面取得适当的进步，并满足老龄化人群的重要需求，临床研究基础设施必须扩展到社区肿瘤学环境中。我们的假设是，在癌症控制护理中的丰富临床试验，尤其是在症状预防，症状管理，综合医学，预防癌症预防，癌症控制和癌症治疗方面，可以通过我们的研究中的艺术医学“基础”中的艺术医学“基础；随后，随后的，重要的癌症护理信息和方法可以从癌症的研究中转移到癌症中，我们的癌症研究中的我们的癌症中心和我们的癌症中心都可以使我们的癌症中心恢复过来。为了响应我们社区肿瘤学家的当前需求和癌症医学领域的当前需求，癌症幸存者的数量增加以及开发研究驱动的人群的护理模型的相关挑战，我们将开发一项癌症控制研究的专注计划，并开发出癌症的治疗方法。癌症控制受癌症影响的患者；亚aim 1d：开发旨在改善癌症幸存者健康的干预试验；结果。可归因于癌症及其治疗的苦难。